NDA 214408 · Accord Hlthcare
Pemetrexed Disodium
Pemetrexed Disodium · Intravenous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jul 19, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,475
329 Phase 3, 251 recruiting
FAERS reports
3,897
3,831 serious, 686 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 850MG BASE/34ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
- PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 100MG BASE/4ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
- PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 1GM BASE/40ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
- PEMETREXED DISODIUM · PEMETREXED DISODIUM EQ 500MG BASE/20ML (EQ 25MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pemetrexed Disodium" as an intervention, any sponsor and status, largest first.
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05055908 · 12,000 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2025
Drug: Pemetrexed plus Pembrolizumab; Pembrolizumab and 1 more · For: Lung Cancer
Sites: Changsha, China
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruiting
NING LIAcademic, hospital or other
NCT06824792 · 3,000 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 29, 2028
Drug: Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE. · For: Advanced Solid Tumors
Sites: Langfang, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00087711 · 1,713 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: pemetrexed; gemcitabine and 1 more · For: Non Small Cell Lung Carcinoma
Sites: Sacramento, California; Torrance, California; Jacksonville, Florida · 134 sites in all
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT06712316 · 1,580 participants (planned) · Start Jan 7, 2025 · Primary completion Jan 2029
Drug: Pumitamig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Concord, California · 366 sites in all
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingCompleted
ECOG-ACRIN Cancer Research GroupResearch network
NCT01107626 · 1,516 participants · Start Oct 25, 2010 · Primary completion Jan 31, 2019
Drug: Paclitaxel; Carboplatin and 2 more · For: Lung Cancer
Sites: Anniston, Alabama; Fairbanks, Alaska; Fairfield, California · 434 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myelosuppression454
- malignant neoplasm progression383
- anaemia196
- diarrhoea182
- nausea179
- platelet count decreased150
- death147
- rash144
- neutropenia139
- white blood cell count decreased139
- pyrexia137
- neutrophil count decreased135
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 8 |
| 2006 | 11 |
| 2007 | 16 |
| 2008 | 13 |
| 2009 | 10 |
| 2010 | 50 |
| 2011 | 80 |
| 2012 | 115 |
| 2013 | 33 |
| 2014 | 27 |
| 2015 | 22 |
| 2016 | 41 |
| 2017 | 83 |
| 2018 | 212 |
| 2019 | 558 |
| 2020 | 484 |
| 2021 | 472 |
| 2022 | 301 |
| 2023 | 248 |
| 2024 | 364 |
| 2025 | 399 |
| 2026 | 325 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pemetrexed Disodium (Pemetrexed Disodium)
2024 spending
$2.4M
Beneficiaries
411
1,858 claims
Per beneficiary
$5,750
$413.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,633,240 |
| 2023 | $2,502,312 |
| 2024 | $2,363,306 |
Part B: Pemetrexed Disodium (Pemetrexed Disodium) · HCPCS J9297
2024 spending
$57K
Beneficiaries
206
574 claims
Per beneficiary
$275
2024 ASP limit $1.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $81,682 |
| 2024 | $56,717 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Clinical Study on Microwave Ablation in Combination with Chemotherapy in Treating Peripheral IIIB-IV Non-Small Cell Lung Cancer.
Zhang YQ, Wu YL, Feng Y, et al. · Cancer Biother Radiopharm 2022 · Randomized Controlled Trial
- Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2004 · Clinical Trial
- Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y, Bagust A, Dickson R, et al. · Health Technol Assess 2007 · Systematic Review
- Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J, Dundar Y, Dodd S, et al. · Cochrane Database Syst Rev 2007 · Systematic Review
- ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
Smit EF, Mattson K, von Pawel J, et al. · Ann Oncol 2003 · Clinical Trial, Clinical Trial, Phase II
- Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X, Raymond E, Laguerre B, et al. · Br J Cancer 2001 · Clinical Trial, Clinical Trial, Phase II
Sponsor: Accord Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.